JP2019531722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531722A5 JP2019531722A5 JP2019515306A JP2019515306A JP2019531722A5 JP 2019531722 A5 JP2019531722 A5 JP 2019531722A5 JP 2019515306 A JP2019515306 A JP 2019515306A JP 2019515306 A JP2019515306 A JP 2019515306A JP 2019531722 A5 JP2019531722 A5 JP 2019531722A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- virus
- stimulating
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 38
- 210000004027 cell Anatomy 0.000 claims 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims 20
- 230000000638 stimulation Effects 0.000 claims 13
- 241000700605 Viruses Species 0.000 claims 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 241000701022 Cytomegalovirus Species 0.000 claims 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 6
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 108010002586 Interleukin-7 Proteins 0.000 claims 5
- 241000700618 Vaccinia virus Species 0.000 claims 5
- 210000005259 peripheral blood Anatomy 0.000 claims 5
- 239000011886 peripheral blood Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 230000000981 bystander Effects 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010067902 Peptide Library Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000700586 Herpesviridae Species 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395438P | 2016-09-16 | 2016-09-16 | |
| US62/395,438 | 2016-09-16 | ||
| PCT/US2017/051284 WO2018052947A1 (en) | 2016-09-16 | 2017-09-13 | Platform for activation and expansion of virus-specific t-cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531722A JP2019531722A (ja) | 2019-11-07 |
| JP2019531722A5 true JP2019531722A5 (enExample) | 2020-10-01 |
| JP7002769B2 JP7002769B2 (ja) | 2022-02-04 |
Family
ID=61619728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515306A Active JP7002769B2 (ja) | 2016-09-16 | 2017-09-13 | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190194619A1 (enExample) |
| EP (1) | EP3512531A4 (enExample) |
| JP (1) | JP7002769B2 (enExample) |
| KR (1) | KR102501827B1 (enExample) |
| CN (1) | CN110177558B (enExample) |
| AU (1) | AU2017326173B2 (enExample) |
| CA (1) | CA3036966A1 (enExample) |
| NZ (1) | NZ751571A (enExample) |
| TW (1) | TWI780069B (enExample) |
| WO (1) | WO2018052947A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| WO2013119947A1 (en) | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| HK1258649A1 (zh) | 2015-09-18 | 2019-11-15 | Baylor College Of Medicine | 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性 |
| US9642906B2 (en) * | 2016-09-16 | 2017-05-09 | Baylor College Of Medicine | Generation of HPV-specific T-cells |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| TW202011977A (zh) * | 2018-04-20 | 2020-04-01 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
| CN108841792A (zh) * | 2018-06-14 | 2018-11-20 | 浙江大学 | 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用 |
| CN112969470A (zh) * | 2018-09-10 | 2021-06-15 | 阿塔拉生物制药股份有限公司 | 用于扩增抗原特异性car-t细胞、组合物的方法及其相关用途 |
| US10772914B1 (en) * | 2019-04-18 | 2020-09-15 | Baylor College Of Medicine | EBV-specific immune cells |
| WO2022056285A1 (en) * | 2020-09-10 | 2022-03-17 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
| CA3146903A1 (en) * | 2019-10-23 | 2021-04-29 | Anish SURI | Modified cytotoxic t cells and methods of use thereof |
| EP4061386A4 (en) * | 2019-11-19 | 2024-01-10 | Acibadem Labmed Saglik Hizmetleri Anonim Sirketi | METHOD FOR PRODUCING MULTIVIRUS-SPECIFIC T CELLS |
| PH12022551290A1 (en) | 2019-11-26 | 2023-11-29 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| WO2021221927A1 (en) | 2020-04-27 | 2021-11-04 | Parsons Corporation | Narrowband iq signal obfuscation |
| MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| EP4239060A4 (en) * | 2020-10-28 | 2024-10-30 | TSD Life Sciences Co., Ltd. | TRANSFORMED IMMUNE CELLS TO INDUCE CHEMOTAXIS AGAINST HETEROGENEOUS IMMUNE CELLS |
| WO2022232797A2 (en) | 2021-04-27 | 2022-11-03 | Baylor College Of Medicine | Virus-specific immune cells expressing chimeric antigen receptors |
| WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| JP2025513890A (ja) | 2022-04-13 | 2025-04-30 | ティクヴァ アロセル プライベート リミテッド | 治療用ｔ細胞製品 |
| EP4509137A1 (en) * | 2023-06-14 | 2025-02-19 | Kuiper, Inc. | A chimeric antigen receptor combinatorial multi-antigen targeted allogeneic t cell immunotherapy with reduced risk of t cell exhaustion, host versus graft rejection, and graft versus host disease |
| GB202318977D0 (en) * | 2023-12-12 | 2024-01-24 | Swarm Oncology Ltd | Method |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002306155A (ja) * | 2001-03-27 | 2002-10-22 | Becton Dickinson & Co | 細胞を培養するための方法および装置 |
| EP1941028A2 (en) | 2005-08-08 | 2008-07-09 | Fondazione Centro San Raffaele Del Monte Tabor | Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes. |
| SI2856876T1 (en) * | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2065462A1 (en) * | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
| WO2010119307A1 (en) * | 2009-04-14 | 2010-10-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells |
| WO2011028531A1 (en) * | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| KR102117350B1 (ko) * | 2010-04-13 | 2020-06-02 | 이뮤노베이티브 테라피스, 엘티디. | 조절 t 세포들의 저해를 위한 방법 및 조성물 |
| BR112014014591A8 (pt) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| WO2013119947A1 (en) * | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| KR101545217B1 (ko) * | 2012-10-29 | 2015-08-18 | 연세대학교 산학협력단 | 줄기세포의 미분화 배양 및 분화 증진을 위한 폴리도파민-펩타이드 고정화 표면 기질 및 그 제조 방법 |
| CN105335280A (zh) * | 2014-07-16 | 2016-02-17 | 北京奇虎科技有限公司 | 程序性能测试方法和装置 |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| JP2018510652A (ja) * | 2015-03-18 | 2018-04-19 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体 |
| US12478670B2 (en) * | 2015-03-20 | 2025-11-25 | Children's National Medical Center | Generating HPV antigen-specific T cells from a naïve T cell population |
| BR112017024431B1 (pt) * | 2015-05-12 | 2021-10-13 | Memorial Sloan Kettering Cancer Center | Uso de uma população de células t alogênicas |
| CN114958738A (zh) * | 2015-06-09 | 2022-08-30 | 淋巴-淋巴细胞活化技术公司 | 用于生产TCRγδ+T细胞的方法 |
| SG11201811563RA (en) * | 2016-06-27 | 2019-01-30 | Yeda Res & Dev | Veto cells generated from memory t cells |
-
2017
- 2017-09-13 NZ NZ751571A patent/NZ751571A/en unknown
- 2017-09-13 CA CA3036966A patent/CA3036966A1/en active Pending
- 2017-09-13 AU AU2017326173A patent/AU2017326173B2/en active Active
- 2017-09-13 EP EP17851424.6A patent/EP3512531A4/en active Pending
- 2017-09-13 US US16/331,494 patent/US20190194619A1/en not_active Abandoned
- 2017-09-13 WO PCT/US2017/051284 patent/WO2018052947A1/en not_active Ceased
- 2017-09-13 JP JP2019515306A patent/JP7002769B2/ja active Active
- 2017-09-13 KR KR1020197010798A patent/KR102501827B1/ko active Active
- 2017-09-13 CN CN201780066129.4A patent/CN110177558B/zh active Active
- 2017-09-15 TW TW106131831A patent/TWI780069B/zh active
-
2022
- 2022-04-28 US US17/661,060 patent/US20220251509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531722A5 (enExample) | ||
| JP7002769B2 (ja) | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム | |
| US10000736B2 (en) | Method for priming of T cells | |
| Qui et al. | CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation | |
| Rydyznski et al. | Boosting vaccine efficacy the natural (killer) way | |
| US12098387B2 (en) | Methods for generating engineered human primary blood dendritic cell lines | |
| BR112016028644B1 (pt) | Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição | |
| CN101258238B (zh) | 抗原呈递细胞的活化处理方法 | |
| JP2019520823A5 (enExample) | ||
| US20040219168A1 (en) | Method for generating highly active human dendritic cells from monocytes | |
| JP6903866B2 (ja) | 血液由来単球の増殖誘導方法 | |
| CN108289913A (zh) | 从未致敏t细胞群体产生hpv抗原特异性t细胞 | |
| Zhou et al. | Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying α-fetoprotein gene or cancer cell lysate | |
| Chen et al. | NK cells require antigen-specific memory CD4+ T cells to mediate superior effector functions during HSV-2 recall responses in vitro | |
| Buonaguro et al. | Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders | |
| Pasetto et al. | Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells | |
| US20100291683A1 (en) | Modified Antigen Presenting Cells and Methods of Use | |
| Zhang et al. | CTL-mediated APC elimination: Constraining effective humoral immunity | |
| Memory | Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? | |
| Chung et al. | of June 9, 2020. | |
| Belkaid et al. | Regulation of antimicrobial immunity | |
| Quinn | Memory CD8+ T cells remain functional throughout an ongoing persistent infection: Implications for antigen-specific immune reconstitution and boosting | |
| Plesa | The effect of antigen dose and viral cytopathicity on CD8 T cell responses | |
| Suttmann et al. | Vaccination/Immunotherapy | |
| Kuis et al. | Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells. |